Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.

The Journal of infectious diseases ·Vol. 188 ·No. 3 ·2003-08-01 ·Pages 424-7

Hill SA, Lloyd PA, McDonald S, Wykoff J, Derse D

Abstract

A single-cycle infection assay with recombinant viral vectors was developed to study human T cell leukemia virus type I (HTLV-I) replication and its inhibition by antiviral agents. The susceptibility of HTLV-I to 6 nucleoside reverse-transcriptase inhibitors was examined. HTLV-I replication was inhibited by tenofovir, abacavir, lamivudine, zalcitabine, stavudine, and zidovudine.

MeSH Terms

Adenine/analogs & derivatives,pharmacology Cell Line Dideoxynucleosides/pharmacology Human T-lymphotropic virus 1/drug effects,physiology Humans Lamivudine/pharmacology Microbial Sensitivity Tests Organophosphonates Organophosphorus Compounds/pharmacology Reverse Transcriptase Inhibitors/pharmacology Stavudine/pharmacology Tenofovir Virus Replication/drug effects Zalcitabine/pharmacology Zidovudine/pharmacology

Chemicals

Dideoxynucleosides Organophosphonates Organophosphorus Compounds Reverse Transcriptase Inhibitors Lamivudine Zidovudine Zalcitabine Tenofovir Stavudine Adenine abacavir

Authors & Affiliations

5 authors, click to expand affiliations / ORCID

Hill Shawn A

Basic Research Laboratory, Center for Cancer Research, Frederick, Maryland, USA.

Lloyd Patricia A

McDonald Shannon

Wykoff Jennifer

Derse David

Article Info

Journal

The Journal of infectious diseases

Abbr.

J Infect Dis

ISSN

0022-1899

DOI

10.1086/376531

Published

2003-08-01

Epub

2003-00-10

Pages

424-7

Language

English

Region

United States

NLM ID

0413675

Subset

External Links

PubMed source DOI: 10.1086/376531 View journal details

Analysis Services

Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.

Contact

WeChat Official Account